Mounjaro vs Zepbound: FDA Labels, Product Identity, and Cost Verification

Start with two brand records, not the ingredient name alone

Both cited FDA labels name tirzepatide as the active ingredient, but each label belongs to a separately named product. Mounjaro is identified as tirzepatide injection under the Mounjaro brand. Zepbound is identified as tirzepatide injection under the Zepbound brand. The shared ingredient is therefore one identity field, not a complete product description. A complete record needs the brand, active ingredient, FDA label, presentation, strength, quantity, dispensing pharmacy, and transaction date.

This distinction keeps searches, benefit checks, and receipts aligned. An ingredient-only note can lose the exact brand requested by a plan, quoted by a pharmacy, or shown on a carton. Record Mounjaro and Zepbound in separate worksheet rows even when both rows say tirzepatide. The purpose is administrative accuracy: a source for one branded product should not silently become evidence for the other. This guide does not extend that identity observation into a medical comparison.

The Mounjaro FDA indication is specific

The cited Mounjaro prescribing information states that Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. Each part belongs in the record: the adjunct language, glycemic-control purpose, type 2 diabetes population, and age boundary. Shortening the statement to a broad ingredient category removes information that the FDA label expressly supplies.

The same cited label does not list chronic weight management as a Mounjaro indication. That is a label-scope observation, not a comment about outcomes or an invitation to use the product outside the label. A content page, quote, or coverage inquiry should not describe Mounjaro as FDA-approved for chronic weight management on the strength of tirzepatide's presence in another brand. Keep the product name attached to the precise indication statement every time it is summarized.

The Zepbound FDA indication record has two listed uses

The cited Zepbound label states that Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. The population conditions and accompanying diet-and-activity language are part of the FDA wording and should remain visible in an exact summary.

That label also lists treatment of moderate to severe obstructive sleep apnea in adults with obesity, again in combination with a reduced-calorie diet and increased physical activity. This is a separate labeled indication with its own condition and adult-population boundary. A faithful comparison reports both Zepbound indications without ranking them against Mounjaro's diabetes indication. These are label categories, not head-to-head measures, and the sources used here support no broader conclusion.

What the indication difference can and cannot tell you

An FDA indication identifies the use and population described in that product's approved prescribing information. It is therefore useful for naming the product correctly, preparing a benefit inquiry, and checking whether a marketing statement matches the cited label. Here, the labels show a diabetes glycemic-control indication for Mounjaro and long-term weight-reduction plus obstructive-sleep-apnea indications for Zepbound. That is the complete comparison this guide draws from the indication sections.

The indication text does not create a result forecast, a ranking, or a household cost. It also does not answer a personal clinical question. This article deliberately omits trial outcomes, adverse-event comparisons, administration schedules, and individual factors. Those topics would move beyond the assigned product-identity scope. For an evidence file, quote the label narrowly, identify its revision, and avoid replacing its population language with a looser description based only on the active ingredient.

Mounjaro presentation identity on the cited label

The Mounjaro label describes a clear, colorless to slightly yellow injection supplied in prefilled single-dose pens or single-dose vials. It lists six presentation strengths: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL. These details belong to product and package identification. They are reproduced to help match records, not to provide administration instructions.

A pharmacy quote should identify more than Mounjaro or tirzepatide. Capture pen or vial, labeled strength, volume, count, days represented by the quote, and the pharmacy or direct channel. The official price page defines its cited fill as four pens and one month's supply. If a quote concerns a different quantity or presentation, place it on another row. Do not normalize unmatched packages into one per-fill figure without documenting the conversion and source.

Zepbound has a broader set of labeled presentations

The cited Zepbound label describes a clear, colorless to slightly yellow injection in prefilled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens. Single-dose pens and vials are listed at six strengths from 2.5 mg/0.5 mL through 15 mg/0.5 mL. Multi-dose vials and KwikPens contain four labeled portions and use presentation-specific total volumes and concentrations. This is package identity, not administration guidance.

Presentation names matter because a manufacturer program, pharmacy quote, supply record, or benefit claim can be limited to one package type. Write the exact name shown in the current source rather than reducing all options to pen or injection. If the available Zepbound record does not state whether it is a single-dose pen, single-dose vial, multi-dose vial, or KwikPen, mark presentation as Not stated and obtain a product-specific quote before comparing amounts.

Use a product-identity key before comparing any commercial field

Build the key in a fixed order: brand, active ingredient, FDA label revision, dosage form, presentation, labeled strength, volume, package count, and transaction channel. Add the National Drug Code from the actual package or claim when available, but do not invent it from a neighboring presentation. The authorized sources for this article do not enumerate those codes, so the worksheet field remains Not stated until a pharmacy, package, or plan record supplies it.

Then match the same key across the prescription record, carton, pharmacy quote, benefit response, manufacturer terms, checkout, and receipt. A mismatch does not prove an error, but it prevents a clean comparison until explained. For example, a four-pen Mounjaro fill and a Zepbound multi-dose presentation should not share an unlabeled quantity cell. Keep source dates beside each field because labels, packages, prices, and program rules can change on different schedules.

The dated Mounjaro price fact needs every qualifier

On 2026-07-23, Lilly's official pricing page stated a Mounjaro list price of $1,112.16 per fill. The page defined one fill as a month's supply consisting of four pens. It also explained that list price is wholesale acquisition cost, the amount Lilly charges wholesalers, and that pharmacy payment can differ. The date, product, four-pen quantity, per-fill term, and list-price category must accompany the number wherever it appears.

That $1,112.16 figure is not a universal checkout amount. Lilly states that actual payment depends largely on prescription-drug insurance, pharmacy charges, discounts, or assistance. Treat it as one dated reference row labeled list price. A pharmacy cash quote belongs on another row, an insured responsibility on another, and any savings result on another. Combining them under cost hides the transaction lane and makes later verification impossible.

A current Zepbound price is Not stated in this source set

The three authorized sources assigned to this article are the two FDA labels and the official Mounjaro pricing page. They do not state a current Zepbound list price, cash price, or manufacturer-program amount for this guide. The correct Zepbound price entry is therefore Not stated, not a remembered figure, a search snippet, or a number imported from another product page. This evidence gap blocks a numerical Mounjaro-versus-Zepbound price verdict.

To refresh the missing field, identify an authorized first-party Zepbound price source and record its check date, exact presentation, strength, package count, channel, insurance status, offer name, term, cap, duration, and change rights. Until that evidence is accepted, use the guide for identity and verification structure only. A missing amount is not zero, unavailable, or necessarily higher. It simply means this article's frozen source set does not establish the number.

Keep coverage, savings, self-pay, and list price separate

The Mounjaro pricing page says commercially insured patients may be eligible for a savings card and that people without insurance or without Mounjaro coverage may have separate self-pay savings options. Those statements describe possible lanes, not approval or a final amount. Government and commercial insurance categories can have different rules. A card, assistance inquiry, pharmacy discount, and plan benefit determination should occupy separate worksheet rows with their own evidence dates.

For coverage, ask the plan about the exact brand and presentation, formulary status, applicable criteria, required documentation, pharmacy network, deductible position, cost-sharing structure, and the response's effective date. Record what the plan actually says rather than inferring from another tirzepatide brand. For self-pay, retain the official offer name, eligible channel, package, amount, expiration, and restrictions. Neither path guarantees stock, continued terms, or a particular household payment.

Use a dated two-column verification worksheet

Give Mounjaro and Zepbound separate columns. Add rows for active ingredient, exact FDA indications, label revision, form, presentation, strength, volume, package quantity, dispensing channel, list price, pharmacy cash quote, insured responsibility, savings program, self-pay program, offer end date, monthly or per-fill cap, and source check date. Enter Not stated whenever the authorized evidence does not answer a row. Do not copy a value across columns merely because the ingredient matches.

For each price entry, preserve the amount due today and the amount expected at the next comparable fill. Save the plan or pharmacy response, offer terms, pre-payment summary, and receipt. If the quoted presentation changes, create a new row rather than overwriting the old identity. The worksheet should make one conclusion easy to audit: which exact product and package was priced, through which channel, under which coverage or self-pay lane, on what date.

Common identity and cost errors to avoid

The first error is treating tirzepatide as the full product name. The second is describing Mounjaro with Zepbound's labeled uses or reducing Zepbound's two indication statements to a generic weight label. The third is calling every injector a pen and dropping whether the record concerns a single-dose or multi-dose presentation. Each shortcut removes a field that the cited labels provide and can disconnect the article from a package or claim.

Commercial errors are equally predictable: treating list price as the pharmacy bill, calling a possible savings path coverage, comparing different package quantities, omitting the check date, or filling an unsupported Zepbound price with a stale number. Avoid a cheapest-brand conclusion when one side is Not stated. Keep this article non-promotional and source-bound. Its defensible result is a clean label and identity map plus a repeatable process for obtaining product-specific commercial evidence.

Source boundary and release status

This guide uses the FDA Mounjaro label, the FDA Zepbound label, and Lilly's Mounjaro pricing page recorded in the Batch 6 research ledger. The source check is dated 2026-07-23. The FDA documents support indication and presentation claims; the pricing page supports Mounjaro's list-price and payment-lane statements. No source in the assigned set supports an exact current Zepbound price, so none is published here.

The article is noindex, under editorial review, and non-promotional. It names Izaiah Tilton as Publisher and has no clinical reviewer or claimed clinical credentials. It contains no active manufacturer or affiliate link. Product pages, labels, program terms, plan responses, and pharmacy quotes can change after the source check. Re-run the identity and commercial worksheet with accepted current evidence before relying on any amount or coverage status.

Sources

1. U.S. Food and Drug Administration · supports mounjaro-zepbound-shared-ingredient-distinct-products, mounjaro-exact-indication, mounjaro-presentations · checked 2026-07-23
2. U.S. Food and Drug Administration · supports mounjaro-zepbound-shared-ingredient-distinct-products, zepbound-exact-indications, zepbound-presentations · checked 2026-07-23
3. Eli Lilly and Company · supports mounjaro-list-price-20260723, mounjaro-payment-lanes · checked 2026-07-23

Next step

Mounjaro and Zepbound share tirzepatide, but the cited FDA labels establish separate product names, indication statements, and presentation records. Mounjaro's label concerns glycemic control in the stated type 2 diabetes populations; Zepbound's label concerns long-term weight reduction in the stated adult populations and moderate to severe obstructive sleep apnea in adults with obesity. For cost, retain the 2026-07-23 date, exact product, presentation, quantity, channel, insurance lane, and final amount. The authorized source set states Mounjaro's $1,112.16 list price per four-pen fill; it does not state a current Zepbound price. Do not fill that gap with an estimate.